Liege, Belgium, 30 June 2022 – 17:45 CEST – In accordance with article 15 of the Belgian Act of 2 May 2007 on the disclosure of major participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions, Mithra Pharmaceuticals SA (the “Company” or “Mithra”) announces the below information, following the issuance of 625,000 new shares today for a total amount of EUR 4,133,933 following the Put Option Notice issued on 13 May, 2022 in the framework of LDA capital commitment agreement entered into April 2020 and extended in April 2022.

Liege, Belgium, 24 June 2022 –18:00 CET – Mithra Pharmaceuticals SA (Euronext Brussels: MITRA) (the “Company” or “Mithra”), a company dedicated to women’s health, today announces that it completed the private placement of 3,871,491 new shares for an aggregate amount of EUR 23.5 million that it had announced on 21 June 2022 (the “Private Placement”).

As a result of the completion of the Private Placement, the share capital of the Company was increased from EUR 33,739,072.34 to EUR 36,573,390.90 and the number of issued and outstanding shares of the Company was increased from 46,085,634 to 49,957,125 ordinary shares, through the issuance of a total of 3,871,491 new shares at an issue price of EUR 6.07 per new share.

Liege, Belgium, 21 June 2022 –07.30 CET – Mithra Pharmaceuticals SA (Euronext Brussels: MITRA) (the “Company” or “Mithra”), a company dedicated to women’s health, today announces that it received subscription commitments from professional, qualified, institutional and other private investors for an aggregate amount of EUR 23.5 million, to subscribe for an aggregate of 3,871,471 new ordinary shares of the Company (being approximately 8.4% of the Company’s outstanding shares) at an issue price of EUR 6.07 per share, representing a 5% discount to the closing share price on Friday 17 June 2022 (the “Private Placement”).

Liege, Belgium, 20 June 2022 – 07:45 CEST – Mithra Pharmaceuticals SA (Euronext Brussels: MITRA) (the “Company” or “Mithra”), a company dedicated to women’s health, today announces its intention to proceed with an equity raise for an aggregate minimum amount of EUR 20 million via a private placement of new ordinary shares with certain professional, qualified, institutional and other private investors only (the “Private Placement”).

Liege, Belgium, 20 June 2022 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces that Mr. François Fornieri resigned from his non-executive director mandate of the Company. Mr. Fornieri ’s decision, founder and major shareholder of the Company, is based on personal reasons.

Liege, Belgium, 13 June 2022 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health today announces, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the “Transparency Law”), that it received two notifications of transparency from Goldman Sachs Group, Inc., with registered offices at Corporation Trust Center, 1209 Orange Street, Wilmington, DE 19801, USA, on 8 & 9, June 2022.

Liege, Belgium, 2 June 2022 – 7:30 CET – Mithra Pharmaceuticals SA (Euronext Brussels: MITRA) (the “Company” or “Mithra”), a company dedicated to Women’s Health, today announces that Goldman Sachs International (“GSI”) has elected to exercise the last call option in relation to the outstanding drawdown of EUR 5 million, and provides additional information on its financing strategy.